(NYSEMKT: AEON) Aeon Biopharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.72%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.39%.
Aeon Biopharma's revenue in 2026 is $0.On average, 3 Wall Street analysts forecast AEON's revenue for 2026 to be $0, with the lowest AEON revenue forecast at $0, and the highest AEON revenue forecast at $0. On average, 3 Wall Street analysts forecast AEON's revenue for 2027 to be $120,067,876, with the lowest AEON revenue forecast at $115,378,893, and the highest AEON revenue forecast at $123,609,554.
In 2028, AEON is forecast to generate $1,831,696,049 in revenue, with the lowest revenue forecast at $1,759,864,831 and the highest revenue forecast at $1,885,569,462.